###
中国临床研究英文版:2026,39(8):1152-1156
本文二维码信息
码上扫一扫!
小柴胡汤加减方联合125I粒子植入在结肠癌肝转移中的疗效
(1. 南京中医药大学附属医院 江苏省中医院介入医学科, 江苏 南京 210029;2. 东部战区总医院介入科, 江苏 南京 210002;3. 南京江北医院麻醉科, 江苏 南京 210048)
Clinical efficacy of modified Xiaochaihu decoction combined with 125I seed implantation in the treatment of colon cancer liver metastasis
摘要
本文已被:浏览 357次   下载 266次
Received:April 06, 2026   Published Online:August 25, 2026
中文摘要: 目的 探讨在125I 粒子植入术基础上联合小柴胡汤加减方对结肠癌肝转移的临床疗效、毒副反应和生存预后的影响。方法 选取2023年1月至2024年12月江苏省中医院收治的42例结肠癌肝转移患者作为研究对象,采用随机数字表法分为对照组与试验组,各21例。两组均行CT引导下125I粒子植入术,试验组于术后第2天加用小柴胡汤加减方口服治疗6 周。比较两组患者治疗前与治疗后3个月血清糖类抗原(CA)125、CA19-9 水平、卡氏功能状态(KPS)评分及治疗过程中的不良反应。随访12个月,对比两组患者客观缓解率(ORR)、总生存期(OS)和无进展生存期(PFS)。结果 治疗后3个月评价,试验组KPS评分显著高于对照组[80(80,85)分vs 70(60,80)分,Z=3.112,P=0.002],恶心呕吐、发热、腹泻不良反应发生率均低于对照组(P<0.05),血清CA125、CA19-9水平两组均较治疗前显著降低(P<0.05),但组间差异无统计学意义(P>0.05)。随访12个月,与对照组比较,试验组ORR、PFS 稍高,但差异无统计学意义[61.9% vs 52.4%,χ2=0.389,P=0.533;5.80(4.90,6.65)个月 vs 5.00(3.90,6.25)个月,log-rank χ2=1.300,P=0.254],两组OS 差异亦无统计学意义(P>0.05)。结论 小柴胡汤加减方联合125I粒子植入治疗结肠癌肝转移,可改善患者体力,降低治疗相关不良反应发生率。
中文关键词: 结肠癌  肝转移  125I粒子  小柴胡汤  毒副反应  预后
Abstract:Objective To investigate the effect of 125I seed implantation combined with modified Xiaochaihu decoction in the treatment of liver metastasis from colon cancer on clinical efficacy,toxicity and survival prognosis. Methods A total of 42 patients with liver metastases from colon cancer treated at Jiangsu Provincial Hospital of Chinese Medicine from January 2023 to December 2024 were selected as the research subjects,and they were divided into a control group and an experimental group,with 21 cases in each group,using a random number table method. All patients underwent CT-guided 125I seed implantation. Furthermore,oral administration of modified Xiaochaihu decoction was initiated in the experimental group on the second day after surgery for 6 weeks. The serum carbohydrate antigen(CA)125,CA19-9 levels,Karnofsky functional status(KPS)score before and 3 months after treatment,and adverse reactions during treatment were compared between the two groups of patients. Follow-up was carried out for 12 months,and the objective response rate(ORR),overall survival(OS)and progression-free survival(PFS)of the two groups were compared. Results Evaluation 3 months after treatment showed that,compared with the control group,the KPS score in the experimental group was significantly higher[80(80,85)vs 70(60,80),Z=3.112,P=0.002],the incidence of adverse reactions such as nausea,vomiting,fever,and diarrhea was lower(P<0.05),and serum CA125 and CA19-9 levels in both groups were significantly lower than before treatment(P<0.05),but the difference between the groups was not statistically significant(P>0.05). After 12 months of follow-up,the experimental group showed slightly higher ORR and PFS compared with the control group,but the differences were not statistically significant[61.9% vs 52.4%,χ2=0.389,P=0.533;5.80(4.90,6.65)months vs 5.00(3.90,6.25)months,log-rank χ2=1.300,P=0.254]. There was also no significant difference in OS between the two groups(P>0.05). Conclusions 125I seed implantation combined with modified Xiaochaihu decoction can improve the physical performance of patients with liver metastasis from colon cancer,and reduce the incidence of treatment-related adverse events.
文章编号:     中图分类号:R735.3 R242    文献标志码:A
基金项目:国家自然科学基金青年科学基金项目(82302321);江苏省中医院科主任学术提升专项基金(Y2022ZR28);江苏省中医院人才引进项目(kgr0259)
引用文本:


Scan with WeChat

Scan with WeChat